Overview of findings from Murdock et al. Cohort heterogeneity (from variation in treatments, timing of MRD samples, and transplantation regimens) may be limiting factors for their prognostic model and therefore for its applicability to other groups of older patients with AML and specific first-line therapies. CR1, first complete remission; CRi, CR with incomplete recovery; HCT-CI, hematopoietic cell transplantation comorbidity index; ITD, internal tandem duplication; non-DT(A), mutations other than DNMT3A, TET2, and ASXL1; wt, wild type.